MRK vs AMGN — Key Metrics
| Metric | MRK (MERCK & CO INC) | AMGN (AMGEN INC) |
|---|---|---|
| Price | 137.78 | 443.89 |
| Market Cap | 339.66 Billion | 240.11 Billion |
| P/E (TTM) | 137.78 | 25.54 |
| P/B (Quarterly) | 8.257 | 18.033 |
| P/S (TTM) | 5.04 | 6.17 |
| Net Profit Margin (TTM) | 3.6 | 24.1 |
| Gross Margin (TTM) | 71.8 | 70.9 |
| ROE (TTM) | 5.3 | 85.6 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Greatly Outperform
Outperform
Recommendation Summary
Stock MRK is projected to greatly outperform the market, stock AMGN is projected to outperform the market. Upfront Recommendation: MRK.
Financial Metrics
| MRK | Metrics | AMGN |
|---|---|---|
| $137.78 | Price | $443.89 |
| — | Market Capitalization | — |
| 137.78 | Price to Earnings Ratio | 25.54 |
| 5.04 | Price to Sales | 6.17 |
| 23.03 | Price to FCF Ratio | 25.06 |
| 7.03 | Price to Gross Profit | 8.7 |
| 11.04 | Price to R&D | 30.63 |
| 8.72 | Price to Current Assets | 6.99 |
MRK vs AMGN at a glance
Merck & CO INC (MRK) and Amgen INC (AMGN) are both Drug Manufacturers - General companies in the Healthcare sector. MRK is the larger, at $339.7 billion in market value against $240.1 billion for AMGN, about 1.4 times the size.
On trailing-twelve-month figures, MRK trades at 137.8 times trailing earnings and AMGN at 25.5; net profit margins are 3.6% and 24.1%.
The Upfront Investment model currently rates MRK Greatly Outperform and AMGN Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.